Tropical sprue

disease
On this page

Also known as idiopathic tropical malabsorption syndromepost-infective tropical malabsorptiontropical enteropathytropical steatorrhea

Summary

Tropical sprue (MONDO:0001078) is a disease and 3 clinical trials. Top therapeutic interventions include rifaximin and rotavirus, live attenuated. A subtype of malabsorption syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nametropical sprue
Mondo IDMONDO:0001078
MeSHD013182
DOIDDOID:10607
ICD-10-CMK90.1
ICD-11316377284
NCITC45428
SNOMED CT47384003
UMLSC0038054
MedGen21300
Is cancer (heuristic)no

Also known as: idiopathic tropical malabsorption syndrome · post-infective tropical malabsorption · tropical enteropathy · tropical steatorrhea

Disease family

This is a subtype of malabsorption syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderintestinal disordermalabsorption syndrometropical sprue

Related subtypes (8): intestinal disaccharidase deficiency, celiac disease, blind loop syndrome, hereditary folate malabsorption, lysine malabsorption syndrome, idiopathic malabsorption due to bile acid synthesis defects, autoimmune enteropathy, lactose intolerance

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE31
PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01375647PHASE3COMPLETEDExploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
NCT01571505PHASE1COMPLETEDExploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)
NCT00858988Not specifiedCOMPLETEDTrial of Rifaximin in the Treatment of Tropical Enteropathy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
RIFAXIMIN41
ROTAVIRUS, LIVE ATTENUATED41